Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chlorpropamide-induced hemolytic anemia.

R Or, E Merin, Y Stupp

    Drug Intelligence & Clinical Pharmacy
    |December 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Correction to: Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.

    Bone marrow transplantation·2021
    Same author

    Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families.

    Journal for immunotherapy of cancer·2019
    Same author

    Regional intra-arterial steroid treatment in 120 patients with steroid-resistant or -dependent GvHD.

    Bone marrow transplantation·2017
    Same author

    Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

    Bone marrow transplantation·2017
    Same author

    Neutrophil Function in Hematological Neoplasia.

    Leukemia & lymphoma·2016
    Same author

    Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.

    Bone marrow transplantation·2015
    Same journal

    Profile of prescription medication in a pediatric population.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    SI units in drug therapeutics.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Physicians' review of significant interventions by clinical pharmacists in inpatient care.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Possible interaction of ranitidine with phenytoin.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Famotidine-associated mental confusion in elderly patients.

    Drug intelligence & clinical pharmacy·1988
    Same journal

    Intravenous self-administration of elemental mercury: efficacy of dimercaprol therapy.

    Drug intelligence & clinical pharmacy·1988
    See all related articles

    A patient developed hemolytic anemia after starting chlorpropamide, a sulfonylurea drug. This suggests no cross-reactivity between glyburide and chlorpropamide in causing this adverse drug reaction.

    Area of Science:

    • Pharmacology
    • Immunology
    • Hematology

    Background:

    • Sulfonylurea drugs are commonly prescribed for type 2 diabetes.
    • Drug-induced hemolytic anemia is a rare but serious adverse effect.

    Observation:

    • A patient on glyburide developed acute intravascular hemolysis upon initiation of chlorpropamide.
    • Serological tests revealed C3 complement component on red blood cells but no immunoglobulins.
    • This pattern suggests an 'innocent bystander' immune mechanism.

    Findings:

    • The case indicates that glyburide and chlorpropamide do not exhibit cross-reactivity in causing sulfonylurea-induced hemolytic anemia.
    • The presence of C3 without immunoglobulins points to a specific immune response targeting red blood cells.

    Related Experiment Videos

    Implications:

    • Clinicians should be aware of the potential for hemolytic anemia with sulfonylurea use.
    • This finding may influence future drug selection and monitoring in diabetic patients with a history of adverse reactions to sulfonylureas.